Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dhaval Bhanusali

Dermatology New York, NY Medical Doctor

NPI 1033436019 CMS profile 1391729

483 10Th Ave Rm 310, New York, NY 10018

Open in the dashboard

General payments

$67,413

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dhaval Bhanusali of New York, NY is reported in the CMS Open Payments database as having received $67,413 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $281 8
2024 General $2,467 5
2023 General $52 2
2022 General $6,790 5
2021 General $2,695 6
2020 General $12,261 25
2019 General $42,867 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dhaval Bhanusali
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Dhaval Bhanusali were reported at $281. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Dhaval Bhanusali Dermatology median Middle half National median
2019 $42,867 $454 $129–$1,240 $163
2020 $12,261 $235 $81–$756 $114
2021 $2,695 $377 $108–$1,108 $132
2022 $6,790 $514 $143–$1,391 $149
2023 $52 $607 $159–$1,674 $160
2024 $2,467 $751 $204–$1,903 $164
2025 $281 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $24,489 32 payments
  2. Galderma Laboratories, L.P. $19,406 45 payments
  3. Almirall LLC $10,709 20 payments
  4. Pfizer Inc. $8,967 19 payments
  5. AbbVie, Inc. $2,874 23 payments
  6. Celgene Corporation $203 9 payments
  7. Merz North America, Inc. $152 2 payments
  8. Aclaris Therapeutics, Inc. $149 1 payment
  9. Arcutis Biotherapeutics, Inc. $137 1 payment
  10. Journey Medical Corporation $76 3 payments
  11. Other $251 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $31,754 18 payments
  2. Consulting Fee $26,341 15 payments
  3. Food and Beverage $6,326 118 payments
  4. Travel and Lodging $2,992 15 payments
Products named General payments · program years 2019–2025
  1. BOTOX COSMETIC $17,399 25 payments
  2. SOOLANTRA $14,931 30 payments
  3. Seysara $10,404 15 payments
  4. ORACEA $7,332 19 payments
  5. EUCRISA $3,720 13 payments
  6. AKLIEF $2,491 6 payments
  7. EPIDUO FORTE $990 15 payments
  8. HUMIRA $257 8 payments
  9. BOTOX $237 6 payments
  10. SKYRIZI $186 10 payments
  11. Other $1,134 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record